A native of Canada, Dr. Naiyer Rizvi received his medical degree from the University of Manitoba, where he also completed his residency. He completed a fellowship at Beth Israel Hospital/Harvard Medical School. He is Director of Thoracic Oncology and leads the Phase 1 immunotherapy program at Columbia University Medical Center. He also holds the Price Chair of Clinical Translational Medicine. Dr Rizvi has led key trials in immunotherapy with anti-PD-1 and anti-PD-L1 in lung cancer. He has authored or co-authored more than 60 peer-reviewed papers, books and book chapters. He currently sits on the editorial board of OncoImmunology.